Harpoon Therapeutics Inc. and Abbvie Inc. have cut their second deal in little more than two years as they embark upon an exclusive worldwide option and license transaction for HPN-217, Harpoon’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback